Chronic idiopathic constipation (CIC) is the most frequent illness encountered by gastroenterologists and account for up to one-half of patient care time. According to a survey, about 14% of the Indians suffer from chronic constipation, higher than the world average which 10%. The US Food and Drug Administration (FDA) has approved plecanatide for chronic idiopathic constipation (CIC) in adults. The current article deals with pharmacology and prescribing information about plecanatide.
CIC is a remarkably common and uneconomic condition that shows a negative impact on the quality of life (QoL) of patients. Constipation is a symptom-based disorder, and it is mainly defined subjectively. In this regard, there is often a lack of agreement between physician and patient’s perception when defining constipation. To better characterize the condition, physicians conceive constipation objectively…
